By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lantheus Medical Imaging 

331 Treble Cove Road
Building 600-2
North Billerica  Massachusetts  01862  U.S.A.
Phone: 800-299-3431 Fax: 978-436-7501


Lantheus Medical Imaging, Inc. is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents. The Company provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Lantheus’ key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon Xe 133 Gas (Xenon 133), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. Lantheus has a pipeline of next-generation and first-in-class agents using Positron Emission Tomography (PET) and MRI technologies.

Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit


President and CEO: Mary Anne Heino

CFO: Jack Crowley

CMO: Cesare Orlandi, MD

VP, Manufacturing and Operations: William Dawes

General Counsel and Sr. VP Strategy and Business Development: Michael Duffy

Sr. VP, Commercial: Tim Healey

CMO: Cesare Orlandi, MD

VP, R&D: Simon Robinson

VP, Quality: Carol Walker

Key Statistics

Ownership: Private

Web Site: Lantheus Medical Imaging

Company News
Lantheus Medical Imaging Announces Public Offering Of 5,200,000 Shares Of Common Stock 9/9/2016 10:58:55 AM
Lantheus Medical Imaging To Host Third Quarter 2015 Earnings Conference Call On November 4, 2015 At 4:30 P.M. Eastern Time 10/22/2015 11:22:09 AM
Massachusetts Debuts Three Biotech IPOs for $235M As Market Roars 6/22/2015 7:06:04 AM
Lantheus Medical Imaging's First Phase 3 Study Of Novel PET Cardiac Imaging Agent Flurpiridaz F 18 Data Show Statistically And Clinically Significant Improvements 5/4/2015 6:53:36 AM
Lantheus Medical Imaging Revives IPO 11/12/2014 6:39:12 AM
Lantheus Medical Imaging Eyes IPO Worth Up To $125 Million 6/26/2014 7:02:19 AM
Lantheus Medical Imaging to Host Third Quarter 2013 Conference Call on November 13, 2013 at 3:00 p.m. Eastern Time 11/7/2013 7:58:26 AM
Lantheus Medical Imaging Releases Preliminary Results from Phase 3 Clinical Trial of Flurpiridaz F 18 for the Detection of Coronary Artery Disease 10/30/2013 7:25:45 AM
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 19, 2013 9/10/2013 6:45:21 AM
Lantheus Medical Imaging to Host Second Quarter 2013 Conference Call on August 8, 2013 at 4:00 p.m. Eastern Time 8/2/2013 7:02:38 AM